The willingness to pay for health improvement under comorbidity ambiguity

Yoichiro Fujii, Yusuke Osaki

Research output: Contribution to journalArticle

Abstract

Accumulated medical information is necessary to determine comorbidity risk between a primary disease and secondary diseases. However, medical decisions often must be made without conclusive evidence because individuals do not have sufficient information. By introducing ambiguity regarding comorbidities, we describe situations in which individuals face a set of plausible comorbidity risks that determines the correlations between primary and secondary diseases. This study examines the conditions under which the willingness to pay for health improvement is larger with comorbidity ambiguity than without it. This study also examines the effect of changes in ambiguity and ambiguity aversion on the willingness to pay.

Original languageEnglish
Pages (from-to)91-100
Number of pages10
JournalJournal of Health Economics
Volume66
DOIs
Publication statusPublished - 2019 Jul 1

Fingerprint

Comorbidity
Health

Keywords

  • Comorbidity ambiguity
  • Cost-benefit analysis
  • Smooth ambiguity model
  • α-maxmin model

ASJC Scopus subject areas

  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

The willingness to pay for health improvement under comorbidity ambiguity. / Fujii, Yoichiro; Osaki, Yusuke.

In: Journal of Health Economics, Vol. 66, 01.07.2019, p. 91-100.

Research output: Contribution to journalArticle

@article{5dc170b10c13467a882c752eeec807cf,
title = "The willingness to pay for health improvement under comorbidity ambiguity",
abstract = "Accumulated medical information is necessary to determine comorbidity risk between a primary disease and secondary diseases. However, medical decisions often must be made without conclusive evidence because individuals do not have sufficient information. By introducing ambiguity regarding comorbidities, we describe situations in which individuals face a set of plausible comorbidity risks that determines the correlations between primary and secondary diseases. This study examines the conditions under which the willingness to pay for health improvement is larger with comorbidity ambiguity than without it. This study also examines the effect of changes in ambiguity and ambiguity aversion on the willingness to pay.",
keywords = "Comorbidity ambiguity, Cost-benefit analysis, Smooth ambiguity model, α-maxmin model",
author = "Yoichiro Fujii and Yusuke Osaki",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.jhealeco.2019.04.002",
language = "English",
volume = "66",
pages = "91--100",
journal = "Journal of Health Economics",
issn = "0167-6296",
publisher = "Elsevier",

}

TY - JOUR

T1 - The willingness to pay for health improvement under comorbidity ambiguity

AU - Fujii, Yoichiro

AU - Osaki, Yusuke

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Accumulated medical information is necessary to determine comorbidity risk between a primary disease and secondary diseases. However, medical decisions often must be made without conclusive evidence because individuals do not have sufficient information. By introducing ambiguity regarding comorbidities, we describe situations in which individuals face a set of plausible comorbidity risks that determines the correlations between primary and secondary diseases. This study examines the conditions under which the willingness to pay for health improvement is larger with comorbidity ambiguity than without it. This study also examines the effect of changes in ambiguity and ambiguity aversion on the willingness to pay.

AB - Accumulated medical information is necessary to determine comorbidity risk between a primary disease and secondary diseases. However, medical decisions often must be made without conclusive evidence because individuals do not have sufficient information. By introducing ambiguity regarding comorbidities, we describe situations in which individuals face a set of plausible comorbidity risks that determines the correlations between primary and secondary diseases. This study examines the conditions under which the willingness to pay for health improvement is larger with comorbidity ambiguity than without it. This study also examines the effect of changes in ambiguity and ambiguity aversion on the willingness to pay.

KW - Comorbidity ambiguity

KW - Cost-benefit analysis

KW - Smooth ambiguity model

KW - α-maxmin model

UR - http://www.scopus.com/inward/record.url?scp=85066108997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066108997&partnerID=8YFLogxK

U2 - 10.1016/j.jhealeco.2019.04.002

DO - 10.1016/j.jhealeco.2019.04.002

M3 - Article

VL - 66

SP - 91

EP - 100

JO - Journal of Health Economics

JF - Journal of Health Economics

SN - 0167-6296

ER -